<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC101597</article-id><article-id pub-id-type="pmcid-ver">PMC101597.1</article-id><article-id pub-id-type="pmcaid">101597</article-id><article-id pub-id-type="pmcaiid">101597</article-id><article-id pub-id-type="pmid">11036017</article-id><article-id pub-id-type="doi">10.1128/aac.44.11.3022-3027.2000</article-id><article-id pub-id-type="publisher-id">0886</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Experimental Therapeutics</subject></subj-group></article-categories><title-group><article-title>Therapeutic Efficacy of GAR-936, a Novel Glycylcycline,  in a Rat Model of Experimental Endocarditis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Murphy</surname><given-names initials="TM">Timothy M.</given-names></name><xref ref-type="author-notes" rid="FN150">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Deitz</surname><given-names initials="JM">Jacqueline M.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Petersen</surname><given-names initials="PJ">Peter J.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mikels</surname><given-names initials="SM">Susan M.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weiss</surname><given-names initials="WJ">William J.</given-names></name></contrib></contrib-group><aff id="N0x9765e78.0x9a6ca80">Infectious Disease Research Section, Antimicrobial Chemotherapy, Wyeth-Ayerst Research, Pearl River, New York 10965</aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: Wyeth-Ayerst Research, 401 N. Middletown Rd., Pearl River, NY 10965. Phone: (845) 732-2220. Fax: (845) 732-5671. E-mail: <email>murphytm@war.wyeth.com</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>11</month><year>2000</year></pub-date><volume>44</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">2787</issue-id><fpage>3022</fpage><lpage>3027</lpage><history><date date-type="received"><day>21</day><month>10</month><year>1999</year></date><date date-type="rev-request"><day>4</day><month>1</month><year>2000</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-10-31 10:56:17.363"><day>31</day><month>10</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac003022.pdf"/><abstract><p>GAR-936, a novel glycylcycline, was investigated with a rat model of experimental endocarditis. It was compared with vancomycin against both vancomycin-susceptible and -resistant <italic>Enterococcus faecalis</italic> and methicillin-resistant <italic>Staphylococcus aureus</italic>. GAR-936 exhibited the lowest MICs (&#8804;0.12 &#956;g/ml) in vitro against each of the isolates tested. Endocarditis was established by placement of a catheter across the aortic valve, followed by intravenous injection of 10<sup>6</sup> CFU of bacteria 48 h later. Treatment with GAR-936 or vancomycin was initiated 24 to 36 h after bacterial infection and administered subcutaneously twice a day for 3 days at ascending doses. GAR-936 reduced bacterial vegetation titers by &gt;2 log<sub>10</sub> CFU, compared to those in untreated controls, for both vancomycin-susceptible and -resistant (VanA and VanB) <italic>E. faecalis</italic> strains and &gt;4 log<sub>10</sub> CFU for a methicillin-resistant <italic>S. aureus</italic> isolate. The glycylcycline was more efficacious at a lower administered dose in the rat model of endocarditis than was vancomycin. The efficacy of GAR-936 in this model was apparently not enhanced by a factor in rat serum, as was observed for vancomycin with a time-kill curve. The results of this study demonstrate the therapeutic potential of GAR-936 for the treatment of enterococcal and staphylococcal infections and warrant further investigation.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>